Health Economics›Classical Hodgkin lymphoma›Relapsed or refractory all lines of therapy

Relapsed or refractory all lines of therapy

Classical Hodgkin lymphoma · 37 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
O-ESHAP Variant #01	—	R 1 540 696	28d	—	—	~3	~R 2 060 430 indirect	—
Bendamustine and Brentuximab vedotin Variant #01	—	R 91 442	21d	—	—	~6	~R 548 654 indirect	—
Brentuximab vedotin and Nivolumab Variant #01 Partial	—	R 85 244	21d	—	—	~4	~R 340 976 indirect	—
Brentuximab vedotin monotherapy Variant #01	—	R 56 829	21d	8.3 mo	—	17	R 966 097 PFS proxy	1
GCD-R Variant #01	—	R 30 934	21d	—	—	~4	~R 123 735 indirect	—
Gemcitabine and Rituximab Variant #01	—	R 30 921	28d	—	~9.5 mo	~6	~R 185 526 PFS proxy · indirect	1
Ifosfamide and Vinorelbine Variant #01	—	R 25 896	21d	—	—	~2	~R 51 792 indirect	—
IGEV Variant #01	—	R 21 643	21d	—	—	~4	~R 86 572 indirect	—
GVD Variant #01	—	R 20 259	21d	—	—	~6	~R 121 555 indirect	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~2	~R 36 719 PFS proxy · indirect	15
MINE Variant #02	—	R 12 872	21d	—	—	~7	~R 90 104 indirect	—
ICE Variant #05	—	R 12 735	—	—	~13.9 mo	~4	~R 50 942 PFS proxy · indirect	—
BeGEV Variant #01	—	R 10 021	21d	—	—	~4	~R 40 085 indirect	—
Bendamustine monotherapy Variant #01	—	R 7 084	—	~16.5 mo	—	~8	~R 56 672 PFS proxy · indirect	2
DexaBEAM Variant #01 Partial	—	R 5 829	28d	—	—	~2	~R 11 659 indirect	—
GCD Variant #01	—	R 5 029	21d	—	—	~4	~R 20 117 indirect	—
GVP Variant #01	—	R 4 285	28d	—	—	~4	~R 17 142 indirect	—
DHAP - time intensified Variant #01	—	R 4 040	—	—	—	~2	~R 8 080 indirect	—
ESHAP Variant #01	—	R 3 886	21d	—	—	~8	~R 31 091 indirect	—
eBEACOPP (Prednisolone) Variant #01 Partial	—	R 3 549	21d	—	—	~3	~R 10 646 indirect	—
eBEACOPP Variant #01 Partial	—	R 3 523	21d	—	—	~8	~R 28 186 PFS proxy · indirect	2
ABVD Variant #01 Partial	—	R 2 885	28d	—	—	~2	~R 5 770 PFS proxy · indirect	4
DHAP Variant #01	—	R 2 495	28d	—	—	~2	~R 4 991 indirect	—
Mini-BEAM Variant #01 Partial	—	R 2 430	28d	—	—	~2	~R 4 859 indirect	—
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	~8.7 mo	—	~24	~R 52 272 PFS proxy · indirect	3
BEACOPP-14 (Prednisolone) Variant #01 Partial	—	R 2 055	14d	—	—	~6	~R 12 329 indirect	—
BEACOPP Variant #01 Partial	—	R 2 042	21d	—	—	~4	~R 8 167 indirect	—
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	~5.2 mo	—	~7	~R 11 705 PFS proxy · indirect	1
Vinblastine monotherapy Variant #01	—	R 1 444	14d	—	—	~2	~R 2 888 indirect	—
Vinorelbine monotherapy Variant #01	—	R 458	21d	~4.0 mo	~9.4 mo	~12	~R 5 490 PFS proxy · indirect	26
Rituximab monotherapy Variant #09 Partial	—	—	28d	~5.2 mo	—	~1	—	3
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	~16.0 mo	~2	—	3
Sintilimab monotherapy Variant #01 Partial	—	—	14d	—	~11.8 mo	~2	—	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~4.6 mo	~12.2 mo	~2	—	28
Zimberelimab monotherapy Variant #01 Partial	—	—	14d	—	—	~52	—	—
Penpulimab monotherapy Variant #01 Partial	—	—	14d	—	—	~2	—	—
Camrelizumab monotherapy Variant #01 Partial	—	—	14d	—	~8.0 mo	~2	—	1

37 of 37 regimens shown